Upgrade to SI Premium - Free Trial

Briefing Docs Show Valeant Pharma (VRX) Brodalumab Prospects are Dim - Wells Fargo

July 15, 2016 1:09 PM
Wells Fargo analyst, David Maris, sees "significant approvability risk" for Valeant Pharma's (NYSE: VRX) IL-17 inhibitor candidate, brodalumab, after today's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA

Next Articles